PRESS RELEASES

Date Title and Summary View
Toggle Summary Regulus Announces U.S. Allowance of Stanford Patent Application Covering miR-181a Function in Immune Cells
miR-181a Patent Exclusively Licensed to Regulus Strengthens Regulus Patent Estate in Immuno-Inflammatory Diseases
View HTML
Toggle Summary Regulus Therapeutics and GlaxoSmithKline Establish New Collaboration to Develop and Commercialize microRNA Therapeutics Targeting miR-122
miR-122 Represents a Novel “Host Factor” Strategy for Treatment of Hepatitis C Infection Further Demonstration of Regulus Leadership in microRNA Science, Technology and Intellectual Property
View HTML
Toggle Summary Regulus, Alnylam and Isis Announce U.S. Allowance of Tuschl III Patent Application Covering miR-21
miR-21 Patent Allowance Strengthens Regulus Leadership
View HTML
Toggle Summary Regulus Therapeutics Present New Pre-clinical Data from Multiple Therapeutic Programs at Keystone Symposium
Regulus scientists and collaborators demonstrate for the first time anti-miR delivery and microRNA target regulation in multiple cell types
View HTML
Toggle Summary Regulus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., Director of Business Development
Regulus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., Director of Business Development CARLSBAD, Calif., Jan 11, 2010 (BUSINESS WIRE) — Regulus Therapeutics Inc., a company developing microRNA therapeutics, today announced the appointment of Zachary A.
View HTML
Toggle Summary Regulus Therapeutics Receives Exclusive License for Intellectual Property on Immuno-inflammatory microRNAs from the California Institute of Technology
Research from the laboratory of Dr. David Baltimore has demonstrated that microRNA-146 and microRNA-155 are key mediators of immune responses
View HTML
Toggle Summary Year in Review and a Look Ahead Webinar-Replay
Year in Review and a Look Ahead Webinar-Replay The replay of our webinar is now available: http://www.videonewswire.com/event.asp?id=64631
View HTML
Toggle Summary Regulus Therapeutics Inc. presents: “MicroRNA: The Year in Review and a Look Ahead”
Webinar to Discuss Recent microRNA Discoveries and Potential Applications in Medicine Scheduled for 3:00 p.m. EST on December 14, 2009 A discussion with leading microRNA scientists Tom Tuschl, Ph.D. Professor at Rockefeller University and Markus Stoffel, MD, Ph.D. Professor at the Swiss Federal Institute of Technology
View HTML
Toggle Summary Regulus Announces U.S. Allowance of Fundamental microRNA Therapeutics Patent Application
Esau patent family broadly covers microRNA therapeutics, including mir-122
View HTML
Toggle Summary Regulus, Alnylam, and Isis Announce First microRNA Patent Grant in Japan from Tuschl III Patent Series
Tuschl III Patent Exclusively Licensed from Max Planck
View HTML